In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

Annals of Neurology

Volumn 47, Issue 4, 2000, Pages 493-503

  Lee, Chong S ^a,d   Samii, Ali ^a   Sossi, Vesna ^b   Ruth, Thomas J ^b   Schulzer, Michael ^a   Holden, James E ^c   Wudel, Jess ^a   Pal, Pramod K ^a   De La Fuente Fernandez, Raul ^a   Calne, Donald B ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b TRIUMF   (Canada)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CARBON 11; DIHYDROTETRABENAZINE; DOPAMINE; FLUORINE 18; LIGAND; METHYLPHENIDATE; PERGOLIDE; TOLCAPONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; HUMAN; ISOTOPE LABELING; NERVE ENDING; NEUROLOGIC DISEASE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

AGED; CARBON RADIOISOTOPES; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOWN-REGULATION; FLUORINE RADIOISOTOPES; HOMOVANILLIC ACID; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 18844471416     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4     Document Type: Article

References (84)

1. Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455
2. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Comparison of neuronal loss in Parkinson's disease and aging. In: Calne DB, Comi G, Crippa D, et al, eds. Parkinsonism and aging. New York: Raven Press, 1989:25-34
3. Zigmond MJ, Abercrombie ED, Berger TW, et al. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-296
4. Hefti F, Melamed E, Wurtman RJ. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res 1980;195:123-137
5. Agid Y, Javoy F, Glowinski J. Hyperactivity of remaining dopaminergic neurones after partial destruction of the nigrostriatal dopaminergic system in the rat. Nat New Biol 1973; 245:150-151
6. Hefti F, Enz A, Melamed E. Partial lesions of the nigrostriatal pathway in the rat: acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology 1985;24:19-23
7. Stachowiak MK, Keller RW Jr, Stricker EM, Zigmond MJ. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J Neurosci 1987;7: 1648-1654
8. Horn AS. Dopamine uptake: a review of progress in the last decade. Prog Neurobiol 1990;34:387-400
9. Miller DW, Abercrombie ED. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-created rats. J Neurochem 1999;72:1516-1522
10. Snyder GL, Keller RWJr, Zigmond MJ. Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals. J Pharmacol Exp Ther 1990;253:867-876
11. Martin WR, Palmer MR, Patlak CS, Calne DB. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 1989;26:535-542
12. Volkow ND, Ding YS, Fowler JS, et al. A new PET ligand for the dopamine transporter: studies in the human brain. J Nucl Med 1995;36:2162-2168
13. Frey KA, Koeppe RA, Kilbourn MR, et at. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996;40:873-884
14. Buu NT. Vesicular accumulation ot dopamine following L-DOPA administration. Biochem Pharmacol 1989;38:1787-1792
15. 3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. J Neurochem 1988;50:1131-1136
16. 11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse 1994;18:152-160
17. Kuhar MJ, Carroll FI, Lewin AH, et al. Imaging transporters for dopamine and other neurotransmitters in brain. In: Reith MEA, ed. Neurotransmitter transporters: structure, function, and regulation. Totowa, NJ: Humana Press, 1997:297-313
18. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19-34
19. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32(Suppl):S125-S127
20. Kilbourn M, Lee L, Vander Borght T, et al. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol 1995;278:249-252
21. 11C]methylphenidate for studying presynaptic dopaminergic neuron with positron emission tomography. J Label Comp Radiopharmaceut 1994;34: 989-997
22. 15O-O, sequentially from the same target chamber. Int J Appl Radiat Isot 1985;36: 107-110
23. 18F]fluorodopa. Appl Radiat Isot 1988;39:1203-1206
24. Spinks TJ, Jones T, Bailey DL, et al. Physical performance of a positron tomograph for brain imaging with retractable septa. Phys Med Biol 1992;37:1637-1655
25. Sossi V, Oakes TR, Chan GL, et al. Quantitative comparison of three- and two-dimensional PET with human brain studies. J Nucl Med 1998;39:1714-1719
26. Vingerhoets FJ, Snow BJ, Schulzer M, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-24
27. 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med 1999;40:283-289
28. Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840
29. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5:584-590
30. Brooks DJ, Salmon EP, Mathias CJ, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990;113:1539-1552
31. Vingerhoets FJ, Schulzer M, Ruth TJ, et al. Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease. J Nucl Med 1996;37:421-426
32. 18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591
33. 11C]dihydrotetrabenazine by dynamic PET: measurement of vesicular monoamine transporter. J Cereb Blood Flow Metab 1996;16:1288-1299
34. Boja JW, McNeill RM, Lewin AH, et al. Selective dopamine transporter inhibition by cocaine analogs. Neuroreport 1992;3: 984-986
35. Meltzer PC, Liang AY, Brownell AL, et al. Substituted 3-phenyltropane analogs of cocaine: synthesis, inhibition of binding at cocaine recognition sites, and positron emission tomography imaging. J Med Chem 1993;36:855-862
36. Ding YS, Fowler JS, Volkow ND, et al. Carbon-11-d-threo-methylphenidate binding to dopamine transporter in baboon brain. J Nucl Med 1995;36:2298-2305
37. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993;34:423-431
38. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997;48:1578-1583
39. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28:547-555
40. 18F]fluorodopa uptake, post-mortem dopaminergic cell counts and striatal dopamine levels. Ann Neurol 1993;34:324-330
41. Pate BD, Kawamata T, Yamada T, et al. Correlation of striatal fluorodopa uptake in the MPTP-monkey with dopaminergic indices. Ann Neurol 1993;34:331-338
42. Sossi V, Holden JE, Chan G, et al. Measuring the BP of four dopaminergic tracers utilizing a tissue input function. In: Gjedde A, Hansen SB, Knudsen GM, eds. Molecular and pharmacological brain imaging. San Diego: Academic Press (In press)
43. Holden JE, Sossi V, Chan G, et al. Effect of population k2 values in graphical estimation of DV ratios of reversible ligand. In: Gjedde A, Hansen SB, Knudsen GM, eds. Molecular and pharmacological brain imaging. San Diego: Academic Press (In press)
44. d plasma input and tissue input derived estimated in DTBZ studies of Parkinson's disease. Neuroimage 1998;7:A18 (Abstract)
45. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology 1998;51:S2-S9
46. Guttman M, Yong VW, Kim SU, et al. Asymptomatic striatal dopamine depletion: PET scans in unilateral MPTP monkeys. Synapse 1988;2:469-473
47. 18F]dopa metabolism in the striatum in Parkinson's disease. Brain 1996;119:2097-2103
48. 18F]dopa-PET study. Brain 1999;122:1637-1650
49. Kilbourn MR. In vivo-in vitro correlations: an example from vesicular monoamine transporters. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press, 1996:3-8
50. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 1996;47:718-726
51. Carlsson A, Winblad B. Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 1976;38:271-276
52. Spokes EG, Koch DJ. Post-mortem stability of dopamine, glutamate decarboxylase and choline acetyltransferase in the mouse brain under conditions simulating the handling of human autopsy material. J Neurochem 1978;31:381-383
53. Tedroff J, Ekesbo A, Rydin E, et al. Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol 1999;46: 359-365
54. Ito Y, Fujita M, Shimada S, et al. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse 1999;31:178-185
55. Calne DB, Langston JW, Martin WR, et al. Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. Nature 1985;317:246-248
56. Barrio JR, Huang SC, Phelps ME. Biological imaging and the molecular basis of dopaminergic diseases. Biochem Pharmacol 1997;54:341-348
57. 18F]fluorodopamine in vivo. J Neurosci Methods 1997; 76:157-165
58. Bowsher RR, Henry DP. Aromatic L-amino acid decarboxylase: biochemistry and functional significance. In: Boulton AA, Baker GB, Yu PH, eds. Neuromethods: series 1: neurochemistry, neurotransmitter enzymes. Clifton, NJ: Humana Press, 1986:33-77
59. Tison F, Normand E, Jaber M, et al. Aromatic L-amino-acid decarboxylase (DOPA decarboxylase) gene expression in dopaminergic and serotoninergic cells of the rat brainstem. Neurosci Lett 1991;127:203-206
60. Li XM, Juorio AV, Paterson IA, et al. Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells. J Neurochem 1992;59:1172-1175
61. Neff NH, Hadjiconstantinou M. Aromatic L-amino acid decarboxylase modulation and Parkinson's disease. Prog Brain Res 1995;106:91-97
62. 18F]Fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography. Brain Res 1991;543:271-276
63. Gjedde A, Reith J, Dyve S, et al. Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci USA 1991;88: 2721-2725
64. Thibaut F, Faucheux BA, Marquez J, et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a post-mortem study using tritiated tetrabenazine. Brain Res 1995; 692:233-243
65. Hoffman BJ, Hansson SR, Mezey E, Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol 1998;19:187-231
66. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 1999;156:138-148
67. Nagatsu T, Kato T, Nagatsu I, et al. Catecholamine-related enzymes in the brain of patients with parkinsonism and Wilson's disease. Adv Neurol 1979;24:283-292
68. Forno LS. Pathology of Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworths, 1982:25-40
69. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(pt 5):2283-2301
70. Damier P, Hirsch EC, Agid Y, Graybiel AM The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122: 1437-1448
71. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880
72. Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427-455
73. Levitt M, Spector S, Sjoerdsma A, Udenfriend S. Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea pig heart. J Pharmacol Exp Ther 1965;148:1-8
74. Lloyd KG, Hornykiewicz O. Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. J Neurochem 1972;19:1549-1559
75. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, et al. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 1993;60: 2175-2180
76. Cumming P, Kuwabara H, Ase A, Gjedde A. Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem 1995;65:1381-1390
77. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain. J Neurochem 1992;58:636-641
78. Naudon L, Leroux-Nicollet I, Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci Lett 1994;173:1-4
79. Vander Borght T, Kilbourn M, Desmond T, et al. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995;294:577-583
80. Wilson JM, Kalasinsky KS, Levey AI, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996;2:699-703
81. Hefti F, Melamed E, Wurtman RJ. The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther 1981;217:189-197
82. 18F]GBR 13119 binding to the dopamine uptake site. Eur J Pharmacol 1992;216:109-112
83. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996;298:27-30
84. Wiener HL, Hashim A, Lajtha A, Sershen H. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier. Eur J Pharmacol 1989;163:191-194